Oncology

Data presented at ESMO Congress 2026 show lifileucel met its feasibility end point in refractory sarcoma, with 80% disease control among 10 patients.

NCCN now lists the brain-penetrant ROS1 inhibitor after progression on earlier TKIs, including as a preferred option for symptomatic brain progression.

The new NCCN Guidelines for Patients: Caregiving for People With Cancer address finances, legal concerns, and household tasks alongside medical management, areas that an expert involved in their development says “often leave people reeling.”

FDA approved talazoparib plus enzalutamide for HRR-mutated metastatic hormone-sensitive prostate cancer after TALAPRO-3 cut progression risk by 52%.

More treatment choices does not always mean better patient outcomes, with care access remaining challenging in Florida.

Oncologists weighted how to choose, manage, and deliver new therapeutics beyond major academic centers.

Financial toxicity affects nearly half of adults with sarcoma in a US cohort, and the authors call for routine screening to guide targeted support.

Full INTerpath-001 results show the individualized mRNA therapy plus pembrolizumab reduced recurrence risk in resected stage IIB-IV melanoma.

The NCCN’s latest esophageal/EGJ guidance raises durvalumab plus FLOT to a category 2A recommendation for PD-L1–negative, diffuse-type disease.

Cosibelimab received an NCCN Category 2A preferred designation for locally advanced CSCC, supported by durable responses and low immune toxicity.

FDA granted accelerated approval to dostarlimab-gxly for dMMR or MSI-H locally advanced rectal cancer based on interim phase 2 AZUR-1 results.

Inconsistent definitions limit pathological response as a soft tissue sarcoma marker, according to a narrative review.

The expanded indication rests on evidence extrapolated from carcinoma in situ, a new FDA approach to closely related forms of bladder cancer.

These phase 3 EXCALIBER-RRMM findings build on earlier MRD-negative complete response results supporting FDA approval of the iberdomide-based regimen.

Tennessee Oncology’s Johnetta Blakely, MD, MS, explains why physicians must review high-stakes AI-assisted orders and how patients view AI in oncology.

OneOncology's Edward "Ted" Arrowsmith, MD, MPH, explains why cost stays out of its pathway process and how point-of-care ordering puts pathways to work.

MedHaul’s platform streamlines nonemergency medical transportation, boosting on-time oncology visits, reducing costs, and helping patients reach critical care across underserved regions.

Tennessee Oncology's Wade Iams, MD, MSCI, discusses insured patients' out-of-pocket costs, platinum shortages, and access to CAR T and BiTE therapies.

Zidesamtinib offers better tolerability in ROS1-positive NSCLC, but adverse effects still need monitoring, and optimal sequencing remains unclear.

Nicolas Ferreyros, of COA, warns IRA drug price negotiation threatens community oncology payments and urges Part B, 340B, and insurer reforms.

Cathy Eng, MD, says flat funding for NCI-sponsored trials discourages site participation and slows data, despite their importance.

Alyssa Schatz, DrPH, MSW, of NCCN, explains how insurance shifts and drug shortages threaten access to cancer care.

OneOncology's Larry Bilbrey discusses why unstructured data limits artificial intelligence and how practices can weigh AI purchases by their payoff.

Experts explain why access to specialty cancer care, open dialogue, and patient education are essential to building trust and making informed treatment decisions.

An intraoperative indocyanine green (ICG) fluorescence imaging protocol in sarcoma surgery detected 14 of 15 positive margins vs 4 of 15 for surgeons, though its specificity was 41.7% vs 88.9%.

Medicaid expansion was associated with lower colorectal cancer mortality, with the largest reductions in Hispanic patients and stage IV disease.

COA's Nicolas Ferreyros discusses real-world survival data for community oncology, health system consolidation, and barriers to CAR T-cell access.